Jump to content
Sign in to follow this  

Comparison - Mirvaso with Rhofade

Recommended Posts

Brimonidine (Mirvaso) and oxymetazoline (Rhofade) are both topical α-adrenergic agonists that have been developed to treat the persistent erythema of rosacea patients. Pharmacological profiling showed brimonidine to be highly selective for the α2 adrenergic receptors, whereas oxymetazoline was much less selective with a significant number of off-target activities, including the 5-hydroxytryptamine 2B (5-HT2B) serotonin receptor.

As the 5-HT2B receptor is potentially involved in drug-induced valvulopathy, the benefit/risk ratio should be carefully considered, especially in patients with cardiovascular disease or other comorbidities.

Drugs in R&D
March 2018, Volume 18, Issue 1, pp 87–90 | Cite as
In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea
David Piwnica, Atul Pathak, Gregor Schäfer, James R. Docherty

Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this